



SUBSECRETARÍA DE SALUD PÚBLICA  
DIVISIÓN DE PLANIFICACIÓN SANITARIA  
DEPARTAMENTO EVALUACIÓN DE TECNOLOGÍAS SANITARIAS Y SALUD BASADA EN EVIDENCIA

## INFORME DE BÚSQUEDA Y SÍNTESIS DE EVIDENCIA DE VALORES Y PREFERENCIAS DE PACIENTES

### Guía de Práctica Clínica Enfermedad de Parkinson tratamiento farmacológico y quirúrgico

#### ESTRATEGIA DE BÚSQUEDA

Se realizó una búsqueda amplia que consideró revisiones sistemáticas y estudios primarios (cualitativos y cuantitativos) que describían valores, preferencias y/o percepciones respecto a la enfermedad y/o calidad de vida, de personas con cáncer avanzado que necesiten alivio del dolor y cuidados paliativos. Se identificaron términos MESH y texto libres asociados a la población.

La búsqueda consideró estudios publicados en **inglés o español** sin restringir el **periodo de búsqueda**. Las **bases de datos consultadas** fueron Pubmed y LILACS (Ver detalle en Anexo 1 “*Términos de Búsqueda y Resultados de la búsqueda*”).

#### SÍNTESIS DE EVIDENCIA SEGÚN PREGUNTA

Una vez ejecutada la búsqueda, se evaluaron los títulos y resúmenes de los estudios encontrados y se filtraron los artículos potencialmente relevantes para ser revisados a texto completo, finalmente se seleccionaron aquellos artículos permitentes y se realizó un resumen por pregunta, a saber:

##### **PREGUNTA 1 ¿EN PERSONAS CON EP EN ETAPA INICIAL MENORES DE 70 AÑOS, SE DEBE USAR AMANTADINA MÁS LEVODOPA EN COMPARACIÓN A USAR LEVODOPA?**

No se encuentra evidencia respecto a valores y preferencias de los pacientes con epilepsia y diskinesia, en cuanto a tratamiento de amantadina+levodopa o sólo levodopa.

##### **PREGUNTA 2 ¿EN PERSONAS CON EP EN ETAPA INICIAL, SE DEBE UTILIZAR LEVODOPA + INHIBIDORES DE COMT EN COMPARACIÓN A LEVODOPA SOLA?**

Estudio aleatorio multicéntrico (Australia, Filipinas, Taiwán y Tailandia) evaluó si el tratamiento con levodopa/carbidopa/entacapone en comparación con levodopa/carbidopa mejora la calidad de vida de pacientes (n=184) con EP, con fluctuaciones motoras nulas o mínimas, con un estadio de entre 1,0 a 2,5 en la escala Hoehn/Yahr, con dosis estables (300 a 800 mg de levodopa). Tras 3 meses de seguimiento, la calidad de vida medida con PDQ-8 (con escala de 0 a 32, donde 32 denota un deterioro constante en todos los dominios), mejoró con una media de 0,8 en el grupo L/C/E,

mientras en el grupo de L/C hubo se deterioró una media 0,6 (diferencia de medias 1,4 puntos estadísticamente significativa,  $p=0,021$ ).

A pesar que este estudio no representa exactamente la preferencia u opinión de los pacientes, pero que con el uso y los resultados de instrumentos de calidad se podría deducir que para estos pacientes podrían ser importantes las mejorías que aparecen como estadísticamente significativas que se observaron en las áreas no motoras: depresión, relaciones personales, comunicación y estigma ( $p<0.05$ ) que reporta el estudio.(1)

### **PREGUNTA 3 ¿EN PERSONAS CON EP EN ETAPA INICIAL MAYORES DE 70 AÑOS, SE DEBE UTILIZAR ANTICOLINERGICOS + LEVODOPA EN COMPARACIÓN A LEVODOPA SOLA?**

No se encuentra evidencia respecto a valores y preferencias de los pacientes con EP

### **PREGUNTA 4. ¿EN PERSONAS CON EP CON COMPLICACIONES MOTORAS, SE DEBE INDICAR ELECTROESTIMULACIÓN CEREBRAL PROFUNDA (ECP) EN COMPARACIÓN A TRATAMIENTO MÉDICO ESTÁNDAR (FARMACOLÓGICO)?**

Un estudio cualitativo australiano que exploró las vivencias y expectativas de 3 mujeres y 8 hombres con EP antes de ECP, resumen que los participantes no estaban seguros de qué esperar después de la operación, tienen la esperanza de una mejor vida, sin tanta dependencia de medicamentos, poder caminar, vivir más fácilmente y tener más libertades. La mayoría conoce a alguien que ya se ha realizado el procedimiento y que están muy satisfechos, lo que mejora sus expectativas(2).

### **PREGUNTA 5 ¿EN PERSONAS CON EP, SE DEBE INDICAR RADIOCIRUGÍA EN COMPARACIÓN A CIRUGÍA TRADICIONAL (LESIONAL: PALIDOTOMÍA Y SUBTALATOMÍA)?**

No se encuentra evidencia respecto a valores y preferencias de los pacientes con Enfermedad de Parkinson

### **PREGUNTA 6 ¿EN PERSONAS CON EP, SE DEBE INDICAR TRATAMIENTO CON CÉLULAS MADRES EN COMPARACIÓN CON TRATAMIENTO MÉDICO ESTÁNDAR (FARMACOLÓGICO)?**

No se encuentra evidencia respecto a valores y preferencias de los pacientes con Enfermedad de Parkinson

### **PREGUNTA 7 DEBERIA USARSE AGONISTAS DOPAMINERGICOS ROPINIROL, PRAMIPEXOL Y ROTIGOTINA VS. LEVODOPA EN PERSONAS CON ENFERMEDAD DE PARKINSON DE NOVO?**

Estudio multicéntrico pragmático abierto del Parkinson's Research Group del Reino Unido siguió en promedio 11,4 años a pacientes con enfermedad de Parkinson temprana (promedio de edad de 57 años al inicio del estudio), de las cuales 42 fueron asignadas aleatoriamente a tratamiento L-dopa/inhibidor descarboxilasa y 67 con bromocriptina. Dentro de los resultados, se observó que la calidad de vida (SF-36) ajustada a los valores iniciales de las escalas Hoehn/Yahr, NWUD y Webster,

fueron significativamente mejor en el brazo de L-dopa en la subescala de “Funcionamiento Físico” y en el “Componente Salud Física” (que suma varias subescalas) del SF-36. No se encontraron diferencias en las otras subescalas por separado (limitaciones de roles debido a problemas físicos; funcionamiento social; dolor corporal, salud mental general, vitalidad y percepción general de salud) y tampoco en la “Componente de salud mental”.

Si bien este estudio no representa exactamente la preferencia u opinión de los pacientes, pero que con el uso y los resultados de instrumentos de calidad se podría deducir que la mejoría en el funcionamiento físico y en la salud física son aspectos pudieran ser relevantes para estos pacientes.(3)

#### **PREGUNTA 8 DEBERÍA USARSE AGONISTA DOPAMINÉRGICO MÁS LEVODOPA VS. LEVODOPA EN ENFERMEDAD DE PARKINSON DE NOVO?**

No se encuentra evidencia respecto a valores y preferencias de los pacientes con Enfermedad de Parkinson

#### **PREGUNTA 9 ¿DEBERÍA USARSE LEVODOPA EN DOSIS BAJA VS. LEVODOPA EN DOSIS ALTA PARA PERSONAS CON ENFERMEDAD DE PARKINSON DE NOVO?**

No se encuentra evidencia respecto a valores y preferencias de los pacientes con Enfermedad de Parkinson

### **Referencias**

1. Fung VSC, Herawati L, Wan Y, Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group. Quality of life in early Parkinson’s disease treated with levodopa/carbidopa/entacapone. *Mov Disord Off J Mov Disord Soc.* 2009 Jan 15;24(1):25–31.
2. Haahr A, Kirkevold M, Hall EOC, Ostergaard K. Living with advanced Parkinson’s disease: a constant struggle with unpredictability. *J Adv Nurs.* 2011 Feb;67(2):408–17.
3. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. *Neurology.* 2008 Aug 12;71(7):474–80.

## ANEXO 1: TÉRMINOS DE BÚSQUEDA Y RESULTADOS DE LA BÚSQUEDA

### Pregunta 1

| (("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Aged"[Mesh:NoExp] OR "under 70"[ti/ab] OR "Elderly"[ti/ab] OR "senior adult"[ti/ab] OR "people aging"[ti/ab] OR "older"[ti/ab]) AND ("initial stage"[ti/ab] OR "first stage"[ti/ab] OR "early stage"[ti/ab] OR "stage 1"[ti/ab] OR "stage I"[ti/ab])) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs]) AND ("Dopamine Agonists"[Mesh] OR "Dopamine Agonists" [Pharmacological Action]) AND ("Levodopa"[Mesh])) AND ("Focus group"[ti/abs] OR "Interview*"[ti/abs] OR "Qualitative Research"[Mesh]) |               |      |            |        |             |
|--|---------------|------|------------|--------|-------------|
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 0    | 0          | 0      | 0           |
| (("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("initial stage"[ti/ab] OR "first stage"[ti/ab] OR "early stage"[ti/ab] OR "stage 1"[ti/ab] OR "stage I"[ti/ab])) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs]) AND ("Dopamine Agonists"[Mesh] OR "Dopamine Agonists" [Pharmacological Action]) AND ("Levodopa"[Mesh]))   |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 0    | 0          | 0      | 0           |
| ("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh]) AND ("Dopamine Agonists"[Mesh] OR "Dopamine Agonists" [Pharmacological Action]) AND ("Levodopa"[Mesh] OR "l-dopa" [ti/ab] NOT "Levodopa carbidopa intestinal gel" NOT "Duoenal" NOT "Duodopa")  |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 55   | 8          | 8      | 2           |
| <b>Títulos de artículos seleccionados</b>  |               |      |            |        |             |
| <ul style="list-style-type: none"> <li>- 2008_Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.</li> <li>- 2006_Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life.</li> <li>- 2004_Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.</li> </ul>  |               |      |            |        |             |
| ((tw:(adulto mayor)) OR (tw:(anciano)) OR (tw:(menor de 70 años)) OR (tw:(personas adultas mayores)) OR (tw:(tercera edad)) OR (tw:(viejo)) OR (tw:(adulto))) AND ((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(estadio 1)) OR (ab:(estadio I)) OR (ab:(estadio inicial)) OR (ab:(primer estadio)) OR (ab:(fase inicial))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (tw:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente ))) AND ((ab:(Agonistas de Dopamina)) OR (ab:(Agonistas Dopaminérgicos))) AND ((ab:(Levodopa)) OR (ab:(l-dopa))) AND ((tw:(Grupos Focales )) OR (tw:(entrevista)) OR (tw:(Investigación Cualitativa)) OR (tw:(Cualitativa)))                                    |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| LILACS   | Todos         | 0    | 0          | 0      | 0           |

((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente )) OR (ab:(Calidad de vida) OR (ab:(EuroQol))) AND ((ab:(Agonistas de Dopamina)) OR (ab:(Agonistas Dopaminérgicos))) AND ((ab:(Levodopa)) OR (ab:(l-dopa)))

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| LILACS | Todos         | 0    | 0          | 0      | 0           |

## Pregunta 2

("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("initial stage"[ti/ab] OR "first stage"[ti/ab] OR "early stage"[ti/ab] OR "stage 1"[ti/ab] OR "stage I"[ti/ab]) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient\* participation"[ti/abs] OR "Patient\* satisfaction"[Mesh:noexp] OR "Patient\* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient\* satisfaction"[ti/abs] OR "communit\* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND (("Catechol O-Methyltransferase Inhibitors"[Mesh] OR "Catechol O-Methyltransferase Inhibitors" [Pharmacological Action] OR "COMT Inhibitor" OR "Catechol-O-methyltransferase inhibitors") AND "Levodopa"[Mesh]) AND ("Focus group"[ti/abs] OR "Interview\*"[ti/abs] OR "Qualitative Research"[Mesh])

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| PUDMED | Todos         | 0    | 0          | 0      | 0           |

("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient\* participation"[ti/abs] OR "Patient\* satisfaction"[Mesh:noexp] OR "Patient\* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient\* satisfaction"[ti/abs] OR "communit\* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND (("Catechol O-Methyltransferase Inhibitors"[Mesh] OR "Catechol O-Methyltransferase Inhibitors" [Pharmacological Action] OR "COMT Inhibitor" OR "Catechol-O-methyltransferase inhibitors" OR "Entacapone") AND "Levodopa"[Mesh])

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| PUDMED | Todos         | 26   | 14         | 10     | 9           |

### Títulos de artículos seleccionados

- 2010\_Quality of life in Parkinson's disease patients following adjunctive tolcapone therapy: results of an open-label, multicenter, community-based trial **(No disponible)**.
- Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
  - o **Estudio de interés citado:** Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
- Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention  
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations **(No disponible)**.
- Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study
- Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone

- 2002\_Cost Effectiveness of Treatment of Parkinson's Disease with Entacapone in the United States **(No disponible)**.

((ab:(Enfermedad de Parkinson)) OR (ab:(Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(estadio 1)) OR (ab:(estadio I)) OR (ab:(estadio inicial)) OR (ab:(primer estadio)) OR (ab:(fase inicial))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente)) OR (ab:(Calidad de vida)) OR (ab:(EuroQol)) OR (ab:(EQ-5D)) OR (ab:(Parkinson's Disease Questionnaire)) OR (ab:(PDQ-39)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQL)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:( PDQUALIF)) OR (ab:( activities of daily living)) OR (ab:(ADL))) AND ((ab:(Inhibidores de Catecol O-Metiltransferasa)) OR (ab:(Inhibidores de COMT)) OR (ab:(inhibidores de la COMT)) OR (ab:(inhibidores de la COMT))) AND (ab:(Levodopa))) AND ((tw:(Grupos Focales)) OR (tw:(entrevista)) OR (tw:(Investigación Cualitativa)) OR (tw:(Cualitativa)))

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| LILACS | Todos         | 0    | 0          | 0      | 0           |

((ab:(Enfermedad de Parkinson)) OR (ab:(Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente)) OR (ab:(Calidad de vida)) OR (ab:(EuroQol)) OR (ab:(EQ-5D)) OR (ab:(Parkinson's Disease Questionnaire)) OR (ab:(PDQ-39)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQL)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:( PDQUALIF)) OR (ab:( activities of daily living)) OR (ab:(ADL))) AND ((ab:(Inhibidores de Catecol O-Metiltransferasa)) OR (ab:(Inhibidores de COMT)) OR (ab:(inhibidores de la COMT)) OR (ab:(inhibidores de la COMT)))

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| LILACS | Todos         | 1    | 0          | 0      | 0           |

### Pregunta 3

((("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Aged"[Mesh:NoExp] OR "over 70"[ti/ab] OR "greater than 70 years"[ti/ab] OR "Elderly"[ti/ab] OR "senior adult"[ti/ab] OR "people aging"[ti/ab] OR "older"[ti/ab]) AND ("initial stage"[ti/ab] OR "first stage"[ti/ab] OR "early stage"[ti/ab] OR "stage 1"[ti/ab] OR "stage I"[ti/ab])) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient\* participation"[ti/abs] OR "Patient\* satisfaction"[Mesh:noexp] OR "Patient\* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient\* satisfaction"[ti/abs] OR "communit\* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND (("Cholinergic Antagonists"[Mesh] OR "Cholinergic Antagonists" [Pharmacological Action] OR "Trihexyphenidyl"[Mesh] OR "Bzotropine"[Mesh] OR "Orphenadrine"[Mesh] OR "Procyclidine"[Mesh]) AND ("Levodopa"[Mesh])) AND ("Focus group"[ti/abs] OR "Interview\*"[ti/abs] OR "Qualitative Research"[Mesh]) Filters: Publication date from 2000/01/01 to 2017/12/31

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| PUDMED | Todos         | 0    | 0          | 0      | 0           |

((("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("initial stage"[ti/ab] OR "first stage"[ti/ab] OR "early stage"[ti/ab] OR "stage 1"[ti/ab] OR "stage I"[ti/ab])) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient\* participation"[ti/abs] OR "Patient\* satisfaction"[Mesh:noexp] OR "Patient\* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient\* satisfaction"[ti/abs] OR "communit\* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's

| Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND (("Cholinergic Antagonists"[Mesh] OR "Cholinergic Antagonists" [Pharmacological Action] OR "Trihexyphenidyl"[Mesh] OR "BENZTROPINE"[Mesh] OR "Orphenadrine"[Mesh] OR "Procyclidine"[Mesh]) AND ("Levodopa"[Mesh])) Filters: Publication date from 2000/01/01 to 2017/12/31  |               |      |            |        |             |
|--|---------------|------|------------|--------|-------------|
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 0    | 0          | 0      | 0           |
| ("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND (("Cholinergic Antagonists"[Mesh] OR "Cholinergic Antagonists" [Pharmacological Action] OR "Trihexyphenidyl"[Mesh] OR "BENZTROPINE"[Mesh] OR "Orphenadrine"[Mesh] OR "Procyclidine"[Mesh]) AND ("Levodopa"[Mesh])) Filters: Publication date from 2000/01/01 to 2017/12/31  |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 8    | 0          | 0      | 0           |
| ((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((tw:(adulto mayor)) OR (tw:(anciano)) OR (tw:(mayor de 70 años)) OR (tw:(personas adultas mayores)) OR (tw:(tercera edad)) OR (tw:(viejo)) OR (tw:(adulto))) AND ((ab:(estadio 1)) OR (ab:(estadio I)) OR (ab:(estadio inicial)) OR (ab:(primer estadio)) OR (ab:(fase inicial))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente)) OR (ab:(Calidad de vida)) OR (ab:(EuroQol)) OR (ab:(EQ-5D)) OR (ab:(Parkinson's Disease Questionnaire)) OR (ab:(PDQ-39)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQL)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:( PDQUALIF)) OR (ab:( activities of daily living)) OR (ab:(ADL))) AND ((ab:(Cholinergic Antagonists)) OR (ab:(Trihexifenidilo)) OR (ab:(Benzotropina)) OR (ab:(Orfenadrina)) OR (ab:(Prociclidina))) AND ((ab:(Levodopa)))) AND ((tw:(Grupos Focales)) OR (tw:(entrevista)) OR (tw:(Investigación Cualitativa)) OR (tw:(Cualitativa))) |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| LILACS   | Todos         | 0    | 0          | 0      | 0           |

#### Pregunta 4

| (("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh] OR "Parkinson") AND ("Motor fluctuations"[ti/ab] OR "off"[ti/ab] OR "on"[ti/ab] OR "Dyskinesias"[Mesh] OR "wearing off" OR "motor complications parkinson's")) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND ("Deep Brain Stimulation"[Mesh] OR "DBS"[ti/ab]) AND "Levodopa"[Mesh])) AND ("Focus group"[ti/abs] OR "Interview*"[ti/abs] OR "Qualitative Research"[Mesh]) |               |      |            |        |             |
|---|---------------|------|------------|--------|-------------|
| Fuente  | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED  | Todos         | 1    | 1          | 1      | 1           |
| <b>Títulos de artículos seleccionados</b>   |               |      |            |        |             |
| - Living with advanced Parkinson's disease: a constant struggle with unpredictability.  |               |      |            |        |             |



((("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh] OR "Parkinson") AND ("Motor fluctuations"[ti/ab] OR "off"[ti/ab] OR "on"[ti/ab] OR "Dyskinesias"[Mesh] OR "wearing off" OR "motor complications parkinson's")) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient\* participation"[ti/abs] OR "Patient\* satisfaction"[Mesh:noexp] OR "Patient\* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient\* satisfaction"[ti/abs] OR "communit\* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND ("Deep Brain Stimulation"[Mesh] OR "DBS"[ti/ab]) AND "Levodopa"[Mesh]))

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| PUDMED | Todos         | 18   | 2          | 2      | 2           |

**Títulos de artículos seleccionados**

- Living with advanced Parkinson's disease: a constant struggle with unpredictability.
- Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease

((("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh] OR "Parkinson") AND ("Motor fluctuations"[ti/ab] OR "off"[ti/ab] OR "on"[ti/ab] OR "Dyskinesias"[Mesh] OR "wearing off" OR "motor complications parkinson's")) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient\* participation"[ti/abs] OR "Patient\* satisfaction"[Mesh:noexp] OR "Patient\* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient\* satisfaction"[ti/abs] OR "communit\* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND ("Deep Brain Stimulation"[Mesh] OR "DBS"[ti/ab]) AND ("Drug Therapy"[Mesh] OR "pharmacotherapy"[ti/ab]))

Filters: Publication date from 2000/01/01 to 2017/12/31

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| PUDMED | Todos         | 4    | 1          | 1      | 1           |

**Títulos de artículos seleccionados**

- Living with advanced Parkinson's disease: a constant struggle with unpredictability.

((("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh] OR "Parkinson"[All Fields]) AND ("Motor fluctuations"[ti] OR "off"[ti] OR "on"[ti] OR "Dyskinesias"[Mesh] OR "wearing off"[All Fields] OR (motor[All Fields] AND ("complications"[Subheading] OR "complications"[All Fields] OR "advanced")) AND ("parkinson disease"[MeSH Terms] OR ("parkinson"[All Fields] AND "disease"[All Fields]) OR "parkinson disease"[All Fields] OR "parkinson's"[All Fields]))) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient\* participation"[ti] OR "Patient\* satisfaction"[Mesh:noexp] OR "Patient\* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti] OR "patient\* satisfaction"[ti] OR "Patient-Centered Care"[Mesh:noexp] OR "Patient Perspectives"[ti] OR "Patient views"[ti] OR "Patient experience"[ti] OR "Quality of Life"[Mesh] OR "EuroQol"[ti] OR "experience"[ti] OR "Parkinson's Disease Questionnaire"[ti] OR "PDQ-39"[ti] OR "Parkinson's Disease Quality of Life Questionnaire"[ti] OR "PDQL"[ti] OR "Parkinson's Disease Quality of Life Questionnaire"[ti] OR "activities of daily living"[ti] OR "ADL"[ti]) AND ("Drug Therapy"[Mesh] OR "pharmacotherapy"[ti]) AND ("2000/01/01"[PDAT] : "2017/12/31"[PDAT]))

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| PUBMED | Todos         | 57   | 10         | 0      | 0           |

**Títulos de artículos seleccionados**

- Immediate versus delayed switch from levodopa/carbidopa to levodopa/ carbidopa/ entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
- Daily motor performance after switching levodopa to melevodopa: an open-label on advanced Parkinson's disease with "delayed-on" and/or"wearing-off".



- Living with advanced Parkinson's disease: a constant struggle with unpredictability.
- [The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off].
- Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.

((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(fluctuaciones motoras)) OR (ab:( Discinesias)) OR (ab:(wearing off)) OR (ab:(off)) OR (ab:(on)) OR (ab:(complicaciones motoras))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente)) OR (ab:(Calidad de vida)) OR (ab:(EuroQol)) OR (ab:(EQ-5D)) OR (ab:(Parkinson's Disease Questionnaire)) OR (ab:(PDQ-39)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQL)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:( PDQUALIF)) OR (ab:( activities of daily living)) OR (ab:(ADL))) AND ((ab:(Estimulación cerebral profunda)) OR (ab:(ECP))) AND ((ab:(Levodopa))) AND ((tw:(Grupos Focales)) OR (tw:(entrevista)) OR (tw:(Investigación Cualitativa)) OR (tw:(Cualitativa)))

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| LILACS | Todos         | 0    | 0          | 0      | 0           |

((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(fluctuaciones motoras)) OR (ab:( Discinesias)) OR (ab:(wearing off)) OR (ab:(off)) OR (ab:(on)) OR (ab:(complicaciones motoras))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente)) OR (ab:(Calidad de vida)) OR (ab:(EuroQol)) OR (ab:(EQ-5D)) OR (ab:(Parkinson's Disease Questionnaire)) OR (ab:(PDQ-39)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQL)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:( PDQUALIF)) OR (ab:( activities of daily living)) OR (ab:(ADL))) AND ((ab:(Estimulación cerebral profunda)) OR (ab:(ECP)))

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| LILACS | Todos         | 6    | 4          | 1      | 1           |

## Pregunta 5

("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient\* participation"[ti/abs] OR "Patient\* satisfaction"[Mesh:noexp] OR "Patient\* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient\* satisfaction"[ti/abs] OR "communit\* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND (("Radiosurgery"[Mesh] OR "Gamma Knife"[ti/ab] OR "Radiosurgeries"[ti/ab] OR "Radiosurgery"[ti/ab] OR "Stereotactic"[ti/ab]) AND ("Pallidotomy"[Mesh] OR "Thalamotomy"[ti/ab] OR "lesion\*"[ti/ab])) AND ("Focus group"[ti/abs] OR "Interview\*"[ti/abs] OR "Qualitative Research"[Mesh])

| Fuente | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
|--------|---------------|------|------------|--------|-------------|
| PUDMED | Todos         | 0    | 0          | 0      | 0           |

("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient\* participation"[ti/abs] OR "Patient\* satisfaction"[Mesh:noexp] OR "Patient\* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient\* satisfaction"[ti/abs] OR "communit\* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND (("Radiosurgery"[Mesh] OR "Gamma Knife"[ti/ab] OR "Radiosurgeries"[ti/ab] OR

| "Radiosurgery"[ti/ab] OR "Stereotactic"[ti/ab]) AND ("Pallidotomy"[Mesh] OR "Thalamotomy"[ti/ab] OR "lesion*"[ti/ab]))   |               |      |            |        |             |
|--|---------------|------|------------|--------|-------------|
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 3    | 0          | 0      | 0           |
| ("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND ("Radiosurgery"[Mesh]) AND ("surgical"[ti/ab]))   |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 0    | 0          | 0      | 0           |
| ("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND (("Radiosurgery"[Mesh]) AND ("surgical"[ti/ab]))   |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUBMED   | Todos         | 3    | 0          | 0      | 0           |
| ((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente)) OR (ab:(Calidad de vida)) OR (ab:(EuroQol)) OR (ab:(EQ-5D)) OR (ab:(Parkinson's Disease Questionnaire)) OR (ab:(PDQ-39)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQL)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:( PDQUALIF)) OR (ab:( activities of daily living)) OR (ab:(ADL))) AND ((ab:(radiocirugía)) OR (ab:( Gamma Knife)) OR (ab:(estereotáxica))) AND ((ab:(palidotomia)) OR (ab:(subtalatomía)) OR (ab:(lesion)) OR (ab:(tradicional)))) AND ((tw:(Grupos Focales)) OR (tw:(entrevista)) OR (tw:(Investigación Cualitativa)) OR (tw:(Cualitativa))) |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| LILACS   | Todos         | 0    | 0          | 0      | 0           |
| ((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente)) OR (ab:(Calidad de vida)) OR (ab:(EuroQol)) OR (ab:(EQ-5D)) OR (ab:(Parkinson's Disease Questionnaire)) OR (ab:(PDQ-39)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQL)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQUALIF)) OR (ab:( activities of daily living)) OR (ab:(ADL))) AND ((ab:(radiocirugía))   |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| LILACS   | Todos         | 0    | 0          | 0      | 0           |

## Pregunta 6

|  |  |  |  |  |  |
|--|--|--|--|--|--|
| ("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND ("Radiosurgery"[Mesh]) AND ("surgical"[ti/ab])) |  |  |  |  |  |
|--|--|--|--|--|--|

| living"[ti/ab] OR "ADL"[ti/ab]) AND ("Stem Cells"[Mesh] AND "Drug Therapy"[Mesh]) AND ("Focus group"[ti/abs] OR "Interview*"[ti/abs] OR "Qualitative Research"[Mesh])  |               |      |            |        |             |
|--|---------------|------|------------|--------|-------------|
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 0    | 0          | 0      | 0           |
| ("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND ("Stem Cells"[Mesh])                                  |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 4    | 1          | 1      | 1           |
| <b>Títulos de artículos seleccionados</b>  |               |      |            |        |             |
| - Intraarterial Autologous Implantation of Adult Stem Cells for Patients with Parkinson Disease  |               |      |            |        |             |
| ((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente)) OR (ab:(Calidad de vida)) OR (ab:(EuroQol)) OR (ab:(EQ-5D)) OR (ab:(Parkinson's Disease Questionnaire)) OR (ab:(PDQ-39)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQL)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:( PDQUALIF)) OR (ab:( activities of daily living)) OR (ab:(ADL))) AND ((ab:(Células madres)) AND (ab:(tratamiento farmacológico))) AND ((tw:(Grupos Focales)) OR (tw:(entrevista)) OR (tw:(Investigación Cualitativa)) OR (tw:(Cualitativa))) |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| LILACS   | Todos         | 0    | 0          | 0      | 0           |
| ((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente)) OR (ab:(Calidad de vida)) OR (ab:(EuroQol)) OR (ab:(EQ-5D)) OR (ab:(Parkinson's Disease Questionnaire)) OR (ab:(PDQ-39)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQL)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:( PDQUALIF)) OR (ab:( activities of daily living)) OR (ab:(ADL))) AND ((ab:(Células madres)))   |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| LILACS   | Todos         | 0    | 0          | 0      | 0           |

## Pregunta 7

|  |  |  |  |  |  |
|--|--|--|--|--|--|
| (("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Aged"[Mesh:NoExp] OR "over 70"[ti/ab] OR "greater than 70 years"[ti/ab] OR "Elderly"[ti/ab] OR "senior adult"[ti/ab] OR "people aging"[ti/ab] OR "older"[ti/ab]) AND ("initial stage"[ti/ab] OR "first stage"[ti/ab] OR "early stage"[ti/ab] OR "stage 1"[ti/ab] OR "stage I"[ti/ab])) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life |  |  |  |  |  |
|--|--|--|--|--|--|

| Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND ("Dopamine Agonists"[Mesh] OR "Dopamine Agonists" [Pharmacological Action]) AND ("Levodopa"[Mesh] OR "l-dopa" [ti/ab])) AND ("Focus group"[ti/abs] OR "Interview*"[ti/abs] OR "Qualitative Research"[Mesh])  |               |      |            |        |             |
|--|---------------|------|------------|--------|-------------|
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 0    | 0          | 0      | 0           |
| (("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("initial stage"[ti/ab] OR "first stage"[ti/ab] OR "early stage"[ti/ab] OR "stage 1"[ti/ab] OR "stage I"[ti/ab])) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND ("Dopamine Agonists"[Mesh] OR "Dopamine Agonists" [Pharmacological Action]) AND ("Levodopa"[Mesh] OR "l-dopa" [ti/ab]))  |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 0    | 0          | 0      | 0           |
| ("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh] OR "EuroQol"[ti/ab] OR "experience"[ti/abs] OR "Parkinson's Disease Questionnaire"[ti/ab] OR "PDQ-39"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQL"[ti/ab] OR "Parkinson's Disease Quality of Life Questionnaire"[ti/ab] OR "PDQUALIF"[ti/ab] OR "activities of daily living"[ti/ab] OR "ADL"[ti/ab]) AND ("Dopamine Agonists"[Mesh] OR "Dopamine Agonists" [Pharmacological Action]) AND ("Levodopa"[Mesh] OR "l-dopa" [ti/ab]) NOT "Levodopa carbidopa intestinal gel" NOT "Duoenal" NOT "Duodopa")   |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 74   | 2          | 2      | 2           |
| <b>Títulos de artículos seleccionados</b>  |               |      |            |        |             |
| <ul style="list-style-type: none"> <li>- 2006_Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life.</li> <li>- 2004_Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.</li> </ul>   |               |      |            |        |             |
| ((tw:(adulto mayor)) OR (tw:(anciano)) OR (tw:(mayor de 70 años)) OR (tw:(personas adultas mayores)) OR (tw:(tercera edad)) OR (tw:(viejo)) OR (tw:(adulto))) AND ((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(estadio 1)) OR (ab:(estadio I)) OR (ab:(estadio inicial)) OR (ab:(primer estadio)) OR (ab:(fase inicial))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente)) OR (ab:(Calidad de vida)) OR (ab:(EuroQol)) OR (ab:(EQ-5D)) OR (ab:(Parkinson's Disease Questionnaire)) OR (ab:(PDQ-39)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQL)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:( PDQUALIF)) OR (ab:( activities of daily living)) OR (ab:(ADL))) AND ((ab:(Agonistas de Dopamina)) OR (ab:(Agonistas Dopaminérgicos))) AND ((ab:(Levodopa)) OR (ab:(l-dopa))) AND ((tw:(Grupos Focales )) OR (tw:(entrevista)) OR (tw:(Investigación Cualitativa)) OR (tw:(Cualitativa))) |               |      |            |        |             |
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| LILACS   | Todos         | 0    | 0          | 0      | 0           |
| ((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(estadio 1)) OR (ab:(estadio I)) OR (ab:(estadio inicial)) OR (ab:(primer estadio)) OR (ab:(fase inicial))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR  |               |      |            |        |             |

| ((ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente)) OR (ab:(Calidad de vida)) OR (ab:(EuroQol)) OR (ab:(EQ-5D)) OR (ab:(Parkinson's Disease Questionnaire)) OR (ab:(PDQ-39)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:(PDQL)) OR (ab:( Parkinson's Disease Quality of Life Questionnaire)) OR (ab:( PDQUALIF)) OR (ab:( activities of daily living)) OR (ab:(ADL))) AND ((ab:(Agonistas de Dopamina)) OR (ab:(Agonistas Dopaminérgicos))) AND ((ab:(Levodopa)) OR (ab:(l-dopa))) |               |      |            |        |             |
|---|---------------|------|------------|--------|-------------|
| Fuente  | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| LILACS  | Todos         | 0    | 0          | 0      | 0           |

## Pregunta 8

| (("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Aged"[Mesh:NoExp] OR "under 70"[ti/ab] OR "Elderly"[ti/ab] OR "senior adult"[ti/ab] OR "people aging"[ti/ab] OR "older"[ti/ab]) AND ("initial stage"[ti/ab] OR "first stage"[ti/ab] OR "early stage"[ti/ab] OR "stage 1"[ti/ab] OR "stage I"[ti/ab])) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs]) AND ("Dopamine Agonists"[Mesh] OR "Dopamine Agonists" [Pharmacological Action]) AND ("Levodopa"[Mesh])) AND ("Focus group"[ti/abs] OR "Interview*"[ti/abs] OR "Qualitative Research"[Mesh]) |               |      |            |        |             |
|--|---------------|------|------------|--------|-------------|
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 0    | 0          | 0      | 0           |

| (("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("initial stage"[ti/ab] OR "first stage"[ti/ab] OR "early stage"[ti/ab] OR "stage 1"[ti/ab] OR "stage I"[ti/ab])) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs]) AND ("Dopamine Agonists"[Mesh] OR "Dopamine Agonists" [Pharmacological Action]) AND ("Levodopa"[Mesh])) |               |      |            |        |             |
|--|---------------|------|------------|--------|-------------|
| Fuente   | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED   | Todos         | 0    | 0          | 0      | 0           |

| ("Parkinson Disease"[Mesh] OR "Parkinsonian Disorders"[Mesh]) AND ("Attitude to Health"[Mesh:noexp] OR "Community Participation"[Mesh] OR "Patient* participation"[ti/abs] OR "Patient* satisfaction"[Mesh:noexp] OR "Patient* Preference"[Mesh:noexp] OR "Consumer Behavior"[Mesh:noexp] OR "consumer satisfaction"[ti/abs] OR "patient* satisfaction"[ti/abs] OR "communit* satisfaction"[ti/abs] OR "Patient-Centered Care"[Mesh:noexp] OR "Share decision making"[ti/abs] OR "Patient Perspectives"[ti/abs] OR "Patient views"[ti/abs] OR "Patient experience"[ti/abs] OR "Quality of Life"[Mesh]) AND ("Dopamine Agonists"[Mesh] OR "Dopamine Agonists" [Pharmacological Action]) AND ("Levodopa"[Mesh] OR "l-dopa" [ti/ab] NOT "Levodopa carbidopa intestinal gel" NOT "Duoenal" NOT "Duodopa") |               |      |            |        |             |
|---|---------------|------|------------|--------|-------------|
| Fuente  | Tipo estudios | N°ro | N°stit/abs | N°manu | N°utilizado |
| PUDMED  | Todos         | 55   | 8          | 8      | 2           |

### **Títulos de artículos seleccionados**

- 2008\_Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
- 2006\_Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life.
- 2004\_Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

((tw:(adulto mayor)) OR (tw:(anciano)) OR (tw:(menor de 70 años)) OR (tw:(personas adultas mayores)) OR (tw:(tercera edad)) OR (tw:(viejo)) OR (tw:(adulto))) AND ((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(estadio 1)) OR (ab:(estadio I)) OR (ab:(estadio inicial)) OR (ab:(primer estadio)) OR (ab:(fase inicial))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (tw:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente ))) AND ((ab:(Agonistas de Dopamina)) OR (ab:(Agonistas Dopaminérgicos))) AND ((ab:(Levodopa)) OR (ab:(l-dopa))) AND ((tw:(Grupos Focales )) OR (tw:(entrevista)) OR (tw:(Investigación Cualitativa)) OR (tw:(Cualitativa)))

| <b>Fuente</b> | <b>Tipo estudios</b> | <b>N°ro</b> | <b>N°stit/abs</b> | <b>N°manu</b> | <b>N°utilizado</b> |
|---------------|----------------------|-------------|-------------------|---------------|--------------------|
| LILACS        | Todos                | 0           | 0                 | 0             | 0                  |

((ab:(Enfermedad de Parkinson)) OR (ab:( Trastornos Parkinsonianos)) OR (ab:(Parkinson))) AND ((ab:(Actitud Frente a la Salud)) OR (ab:(Participación de la Comunidad)) OR (ab:(Participación del Paciente )) OR (ab:(Satisfacción del Paciente)) OR (ab:(Prioridad del Paciente)) OR (ab:(Preferencia del paciente)) OR (ab:(Comportamiento del Consumidor)) OR (ab:(Satisfacción del consumidor)) OR (ab:(Atención Dirigida al Paciente )) OR (ab:(experiencia del Paciente )) OR (ab:(Calidad de vida)) OR (ab:(EuroQol))) AND ((ab:(Agonistas de Dopamina)) OR (ab:(Agonistas Dopaminérgicos))) AND ((ab:(Levodopa)) OR (ab:(l-dopa)))

| <b>Fuente</b> | <b>Tipo estudios</b> | <b>N°ro</b> | <b>N°stit/abs</b> | <b>N°manu</b> | <b>N°utilizado</b> |
|---------------|----------------------|-------------|-------------------|---------------|--------------------|
| LILACS        | Todos                | 0           | 0                 | 0             | 0                  |